Received Sep 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 7+ | LM2215 | IM / RA |
| FLU3 | INFLUENZA (SEASONAL) (FLUZONE) | SANOFI PASTEUR | UNK | UT8437DA | IM / LA |
Patient developed SIRVA following the Covid-19 vaccination on 8/29/2024. The SIRVA was detected when the patient came into the office on 7/25/25 for right shoulder pain.
Chronic pain, primary insomnia, type 2 diabetes mellitus, diabetic nephropathy, major depressive disorder, hypertensive chronic kidney disease, atherosclerotic heart disease, left carotid stenosis, peripheral vascular disease, atherosclerosis of aorta, COPD with chronic bronchitis, chronic kidney disease stage 3a, hypothyroidism (acquired), neurogenic pruritus, obstructive sleep apnea
Isosorbide mononitrate ER 30 mg tablet extended release, Crestor 40 mg, Detrol LA 4 mg extended release, Cymbalta 60 mg delayed release particles 2 caps once a day, Furosemide 20 mg tablet, Farxiga 10 mg tablet once a day, Metformin Hcl ER
Celexa, effexor, paxil, codeine, demerol, allergra, moxifloxacin, metronidazole, lisinopril, losartan, spiriva handihaler, thimersol, flonase, quinones
x-ray on 7/25/25, MRI upcoming on 9/7/25, sports medicine evaluation on 8/26/25